Literature DB >> 30319326

Standard Neoadjuvant Treatment in Early/Locally Advanced Breast Cancer.

Cristina Pernaut1, Flora Lopez1, Eva Ciruelos1.   

Abstract

Neoadjuvant treatment allows us to improve surgical results and test new drugs. In recent years, there have been significant advances in the field of neoadjuvant treatment, including hormonal neoadjuvant therapy in luminal tumors, double blockade in HER2-positive tumors, and the use of platinum salts in triple-negative tumors.

Entities:  

Keywords:  Breast cancer; Neoadjuvant treatment; Pathological complete response

Year:  2018        PMID： 30319326      PMCID： PMC6170899          DOI： 10.1159/000491759

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  23 in total

1.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Authors:  Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; Sergey Tjulandin; Milvia Zambetti; Federico Vazquez; Mikhail Byakhow; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belén Ojeda; Mauro Mansutti; Alla Bozhok; Roberta Baronio; Andrea Feyereislova; Claire Barton; Pinuccia Valagussa; Jose Baselga
Journal:  Lancet       Date:  2010-01-30       Impact factor: 79.321

2.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Authors:  Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch
Journal:  Lancet Oncol       Date:  2014-04-30       Impact factor: 41.316

3.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

4.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

5.  Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

Authors:  Michael Untch; Sibylle Loibl; Joachim Bischoff; Holger Eidtmann; Manfred Kaufmann; Jens-Uwe Blohmer; Jörn Hilfrich; Dirk Strumberg; Peter A Fasching; Rolf Kreienberg; Hans Tesch; Claus Hanusch; Bernd Gerber; Mahdi Rezai; Christian Jackisch; Jens Huober; Thorsten Kühn; Valentina Nekljudova; Gunter von Minckwitz
Journal:  Lancet Oncol       Date:  2012-01-17       Impact factor: 41.316

Review 6.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

7.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Authors:  B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

8.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

Authors:  A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976

9.  Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.

Authors:  Rodrigo Goncalves; Katherine DeSchryver; Cynthia Ma; Yu Tao; Jeremy Hoog; Maggie Cheang; Erika Crouch; Neha Dahiya; Souzan Sanati; Michael Barnes; Luis Otávio Zanatta Sarian; John Olson; Donald Craig Allred; Matthew J Ellis
Journal:  Breast Cancer Res Treat       Date:  2017-06-13       Impact factor: 4.872

Review 10.  Preoperative chemotherapy for women with operable breast cancer.

Authors:  J S D Mieog; J A van der Hage; C J H van de Velde
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more
  7 in total

Review 1.  Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field.

Authors:  Santiago Escrivá-de-Romaní; Miriam Arumí; Esther Zamora; Meritxell Bellet
Journal:  Breast Care (Basel)       Date:  2018-08-14       Impact factor: 2.860

2.  Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers.

Authors:  Kuo Chen; Jin Zhang; Narasimha M Beeraka; Chengyun Tang; Yulia V Babayeva; Mikhail Y Sinelnikov; Xinliang Zhang; Jiacheng Zhang; Junqi Liu; Igor V Reshetov; Olga A Sukocheva; Pengwei Lu; Ruitai Fan
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

3.  Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.

Authors:  Dena Firouzabadi; Amirreza Dehghanian; Alireza Rezvani; Laleh Mahmoudi; Abdolrasoul Talei
Journal:  BMC Cancer       Date:  2021-01-11       Impact factor: 4.430

4.  Synergistic Effect of Doxorubicin and siRNA-Mediated Silencing of Mcl-1 Using Cationic Niosomes against 3D MCF-7 Spheroids.

Authors:  Supusson Pengnam; Samarwadee Plianwong; Prasopchai Patrojanasophon; Widchaya Radchatawedchakoon; Boon-Ek Yingyongnarongkul; Praneet Opanasopit; Purin Charoensuksai
Journal:  Pharmaceutics       Date:  2021-04-14       Impact factor: 6.321

5.  Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.

Authors:  Zhuo Zhang; Hanxu Zhang; Chao Li; Qian Xiang; Ling Xu; Qianxin Liu; Xiaocong Pang; Wenjia Zhang; Hong Zhang; Shuang Zhang; Xuening Duan; Yinhua Liu; Yimin Cui
Journal:  Thorac Cancer       Date:  2021-11-09       Impact factor: 3.500

Review 6.  Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis.

Authors:  Agampodi Danushi M Gunasekara; Thunyarat Anothaisintawee; Sitaporn Youngkong; Nguyen T Ha; Gareth J McKay; John Attia; Ammarin Thakkinstian
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

7.  Machine Learning Models and Multiparametric Magnetic Resonance Imaging for the Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Carmen Herrero Vicent; Xavier Tudela; Paula Moreno Ruiz; Víctor Pedralva; Ana Jiménez Pastor; Daniel Ahicart; Silvia Rubio Novella; Isabel Meneu; Ángela Montes Albuixech; Miguel Ángel Santamaria; María Fonfria; Almudena Fuster-Matanzo; Santiago Olmos Antón; Eduardo Martínez de Dueñas
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.